insights_auto
Why is AIM up 3.82%?
Dive Deeperchevron_right
AIM:NYSEAMERICAN
AIM ImmunoTech Inc
$ 0.14
arrow_upward
+3.82%(+0.0050) 1D
$ 0.14
arrow_upward
+2.28% (+0.0031)bedtimeAfter hours
Closed: 11-р сарын 17, 16:00:00 (GMT-5) · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for AIM...
Open
$ 0.13
High
$ 0.14
Low
$ 0.13
Mkt. cap
5.47 сая
Avg. vol.
541.91 мян
Volume
496.89 мян
52-wk high
$ 1.88
52-wk low
$ 0.12
EPS
-$ 2.46
Beta
1.32
Shares outstanding
39.92 сая
No. of employees
20
Open
$ 0.13
High
$ 0.14
Low
$ 0.13
Mkt. cap
5.47 сая
Avg. vol.
541.91 мян
Volume
496.89 мян
52-wk high
$ 1.88
52-wk low
$ 0.12
EPS
-$ 2.46
Beta
1.32
Shares outstanding
39.92 сая
No. of employees
20
News stories
From web sources and news partners
Investing.com
·
16 цагийн өмнө
aim immunoTech CEO Equels buys $5,130 in common stock
Profile
AIM ImmunoTech Inc., formerly known as Hemispherx Biopharma Inc., is a biopharmaceutical company based in Ocala, Florida that is focused on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Founded in 1990, the company has twenty-three employees.
The company has created an immunomodulatory double stranded RNA drug called Ampligen.
It is also developing Ampligen to use as a treatment for multiple cancer tumor types, COVID-19 and chronic fatigue syndrome. Wikipedia
About AIM ImmunoTech Inc
CEO-
Employees20
Founded1966
HeadquartersФиладельфия, Пеннсилвани, Америкийн Нэгдсэн Улс
SectorHealth Care
Industry-
Websiteaimimmuno.com